Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 10NET 8Gastrointestinal 1CNS 1

Conditions

Glioblastoma 14Brain Neoplasms 12Glioma 11Astrocytoma 9Meningioma 7Central Nervous System Neoplasms 7Gliosarcoma 6Diffuse Intrinsic Pontine Glioma 6Recurrence 4Neurofibromatosis 2 4Tuberous Sclerosis 3Pheochromocytoma 3Paraganglioma 3Neuroma, Acoustic 3Rhabdomyosarcoma 2Oligodendroglioma 2Neurofibromatosis 1 2Neuroendocrine Tumors 2Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2von Hippel-Lindau Disease 1Zollinger-Ellison Syndrome 1Vestibulocochlear Nerve Diseases 1Tuberous Sclerosis 2 1Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Seizures 1Sarcoma 1Salivary Gland Neoplasms 1

Interventions

gallium Ga 68 dotatate 2Erlotinib Hydrochloride 2pertuzumab 1fluorodopa F 18 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Immunotherapy 1Everolimus 1Drug Therapy 1Biological Therapy 1Biological Factors 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × Everolimus × CNS × Clear all
NCT00843531 2020-09-29

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

University of California, San Francisco

Phase 2 Terminated
17 enrolled 10 charts
CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡